Spain's PharmaMar and Jazz Pharmaceuticals have signed a $1 billion license agreement for the lung cancer drug lurbinectedin in the US, which is being teed up for a launch in 2020.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback